arrow
M

Maik Pietzner

University of Cambridge
H指数:42
被引数:8,106

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Systematic comparison of affinity plasma proteomic technologies across multiple cohorts reveals generalizability of proteomic prediction

多队列中亲和血浆蛋白质组学技术的系统性比较揭示了蛋白质组预测的普适性

2026-10-080
OA
A comprehensive proteomic and transcriptomic mapping study found porcine and human kidneys exhibit a profoundly altered biological profile during warm ex vivo perfusion

一项全面的蛋白质组学和转录组学映射研究显示,猪和人类肾脏在温暖<em>ex vivo</em>灌注期间表现出深刻改变的生物学特征

2026-09-230
OAAI
Proteomics identify disease-associated variants in patients with rare diseases undiagnosed after genome sequencing

蛋白质组学鉴定基因组测序后仍无法诊断的罕见病患者中的疾病相关变异

2026-09-090
PRE
Nanoparticle-enriched mass spectrometry proteomics in British South Asians identifies links between genetic variants, plasma protein levels and disease risk

纳米颗粒富集质谱蛋白质组学在英国南亚人群中鉴定出遗传变异、血浆蛋白质水平与疾病风险之间的关联

2026-07-240
OA
Tissue origins of the plasma proteomic response to glucose ingestion in humans

葡萄糖摄入后人类血浆蛋白质组反应的组织来源

2026-07-170
OAAI
A predictive atlas of disease onset from retinal fundus photographs: a modelling study using data from population-based cohorts

基于人群队列数据的眼底照片疾病发作预测图谱:一项建模研究

2026-03-190
OAAI
Damaging mutations in liver X receptor-α are hepatotoxic and implicate cholesterol sensing in liver health

肝脏X受体-α 的破坏性突变具有肝毒性,并暗示肝脏健康中的胆固醇感应

2024-09-250
OAAI
Proteomic signatures improve risk prediction for common and rare diseases

蛋白质组学特征改善了常见和罕见疾病的风险预测

2024-07-224
OA
Identifying proteomic risk factors for overall, aggressive, and early onset prostate cancer using Mendelian Randomisation and tumour spatial transcriptomics

使用孟德尔随机化和肿瘤空间转录组学确定总体,侵袭性和早发性前列腺癌的蛋白质组学危险因素

2024-07-010
OAAI
Identifying therapeutic targets for cancer among 2074 circulating proteins and risk of nine cancers

在2074循环蛋白质中确定癌症治疗靶点和9种癌症的风险

2024-04-291
OAAI
Identifying proteomic risk factors for overall, aggressive and early onset prostate cancer using mendelian randomization and tumor spatial transcriptomics
2024-03-221
PRE